The MS4A4A and MS4A6A gene cluster on chromosome 11q12 represents a critical regulatory pathway in Alzheimer's disease pathogenesis. A landmark 2026 study in Neuron demonstrated that these two genes cooperate to negatively regulate TREM2 signaling on microglia, providing a mechanistic explanation for how MS4A variants increase AD risk through impaired microglial function. This causal chain reveals a novel therapeutic target: blocking the MS4A4A-MS4A6A interaction to enhance TREM2 signaling and restore microglial phagocytosis.
The MS4A (Membrane-Spanning 4-A) gene cluster on chromosome 11q12.2 contains multiple genes with emerging roles in neuroimmunity:
| Gene |
Chromosome |
Primary Expression |
AD Association |
| MS4A4A |
11q12.2 |
Microglia, myeloid cells |
Risk (OR ~1.10-1.15) |
| MS4A6A |
11q12.2 |
Microglia, myeloid cells |
Risk (OR ~1.10-1.15) |
| MS4A7 |
11q12.2 |
Low in brain |
Some association |
| MS4A2 |
11q12.2 |
Mast cells |
No AD link |
Genome-wide association studies have identified multiple variants in the MS4A locus that:
- Modulate CSF sTREM2 levels: Certain MS4A4A variants are associated with reduced soluble TREM2 in cerebrospinal fluid
- Affect microglial activation states: Expression quantitative trait loci (eQTLs) influence microglial transcriptional programs
- Modify disease progression: Some variants correlate with faster cognitive decline
The lead GWAS variants include:
- rs1582763 (MS4A4A): Associated with lower CSF sTREM2, increased AD risk
- rs670139 (MS4A6A): Modulates MS4A4A expression and TREM2 biology
- rs6102056 (MS4A4A): eQTL affecting microglial MS4A4A expression
flowchart TD
subgraph "Genetic Risk"
A["MS4A4A Risk<br/>Variants"] --> B["Elevated MS4A4A<br/>Expression"]
A2["MS4A6A Risk<br/>Variants"] --> B2["Increased MS4A6A<br/>Stability"]
end
subgraph "Molecular Interaction"
B --> C["MS4A4A Binds<br/>MS4A6A"]
B2 --> C
C --> D["MS4A4A-MS4A6A<br/>Complex Formation"]
D --> E["DAP12 Co-receptor<br/>Sequestration"]
end
subgraph "TREM2 Dysfunction"
E --> F["Reduced TREM2-DAP12<br/>Signaling"]
F --> G["Decreased sTREM2<br/>Shedding"]
G --> H["Impaired Microglial<br/>Activation"]
end
subgraph "Cellular Consequences"
H --> I1["Reduced Phagocytosis"]
H --> I2["Decreased Microglial<br/>Viability"]
H --> I3["Impaired Lysosomal<br/>Function"]
H --> I4["Altered Inflammatory<br/>Response"]
end
subgraph "Disease Outcomes"
I1 --> J["Amyloid Plaque<br/>Accumulation"]
I2 --> K["Neurodegeneration"]
I3 --> J
I4 --> K
J --> L["Tau Pathology<br/>Spread"]
K --> M["Cognitive<br/>Decline"]
L --> M
end
subgraph "Therapeutic Intervention"
N["MS4A4A<br/>Antagonists"] --> O["Block MS4A4A-MS4A6A<br/>Interaction"]
O --> P["Restore TREM2<br/>Signaling"]
P --> Q["Enhanced Microglial<br/>Function"]
Q --> R["Improved Aβ<br/>Clearance"]
end
style N fill:#c8e6c9,stroke:#333
style R fill:#c8e6c9,stroke:#333
The key discovery from the 2026 study is that MS4A4A and MS4A6A cooperate to regulate TREM2:
- Direct Complex Formation: MS4A4A can directly interact with TREM2 on the cell surface
- Primary Indirect Mechanism: MS4A4A's effect on TREM2 is primarily mediated through MS4A6A
- DAP12 Sequestration: The MS4A4A-MS4A6A complex sequesters DAP12 (TYROBP), the essential co-receptor for TREM2 signaling
- Competitive Inhibition: By binding DAP12, the MS4A complex prevents TREM2-DAP12 interaction and downstream signaling
Normal TREM2 signaling involves:
TREM2 (ligand: Aβ, lipids) → DAP12 (ITAM) → SYK activation →
→ PI3K/AKT pathway → Microglial activation, phagocytosis, survival
When MS4A4A/MS4A6A sequester DAP12:
- Reduced SYK phosphorylation
- Impaired PI3K/AKT signaling
- Decreased microglial survival and function
| Gene |
Mechanism |
Therapeutic Strategy |
| MS4A4A/MS4A6A |
Negative regulation of TREM2 via DAP12 sequestration |
Antagonists to block interaction |
| TREM2 |
Direct receptor dysfunction |
Agonists (AL002, AL003) |
| PLCG2 |
Downstream signaling defect |
Activators |
| CD33 |
Inhibitory ITIM signaling |
Antagonists |
| INPP5D |
PIP3 hydrolysis imbalance |
Stage-dependent modulators |
- Mechanism: Block the MS4A4A-MS4A6A interaction to free DAP12 for TREM2
- Advantage: Upstream of TREM2 - could enhance all TREM2-mediated functions
- Challenge: Must achieve brain penetration and target microglia specifically
- Mechanism: Enhance DAP12 availability or stability independent of MS4A
- Approach: Small molecules that prevent MS4A-DAP12 binding
- Combine with MS4A4A/MS4A6A inhibition for synergistic effect
- AL002 and AL003 continue in clinical trials[@trem2023]
- CSF sTREM2: Reduced in MS4A4A risk allele carriers - indicates impaired TREM2 signaling
- CSF MS4A4A: Elevated in AD - potential biomarker for target engagement
- PET Amyloid: Increased plaque burden in carriers of risk variants
The MS4A4A/MS4A6A-TREM2 pathway occupies a unique position in the AD mechanistic landscape:
| Chain |
Genetic Validation |
Mechanistic Clarity |
Therapeutic Tractability |
Status |
| MS4A4A/MS4A6A → TREM2 |
Strong (GWAS + functional) |
High (2026 study) |
High (antagonists feasible) |
Discovery |
| TREM2 → Microglial Dysfunction |
Strong (GWAS + rare variants) |
High |
Medium (agonists) |
Phase 2 |
| PLCG2 → Phagocytosis |
Strong (protective variant) |
High |
High |
Discovery |
| CD33 → Phagocytosis Inhibition |
Moderate |
High |
Medium |
Preclinical |
- Cooperative Mechanism: Unlike single-gene effects, MS4A4A and MS4A6A must cooperate - provides dual targeting opportunity
- Upstream of TREM2: Blocking the negative regulator could be more effective than directly activating TREM2
- Microglia-Specific: Expression largely restricted to myeloid cells - potential for targeted therapy
- Biomarker Availability: CSF sTREM2 provides direct read-out of mechanism
- MS4A4A/MS4A6A risk allele carriers: May benefit most from TREM2-enhancing therapies
- Low CSF sTREM2 patients: Indicator of impaired TREM2 signaling - potential responders
- Amyloid-positive early AD: Ideal population for intervention
- MS4A antagonist + TREM2 agonist: Double enhancement of microglial function
- MS4A antagonist + anti-amyloid antibody: Enhanced clearance + reduced plaque formation
- MS4A antagonist + anti-tau therapy: Address both amyloid and tau pathology